Colon News and Research

RSS

Give a Scan: First open access website for CT scans and clinical data

Lung Cancer Alliance, the only national non-profit dedicated to providing support and advocacy for those living with or at risk for lung cancer, announced today the launching of the first open access website for CT scans and clinical data donated by patients, called Give a Scan, that will increase and accelerate research for lung cancer screening, diagnosis, treatment and drug development.

8 Jun 2010

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Synta Pharmaceuticals Corp. announced that clinical results for two Phase 1 trials of STA-9090 in solid tumors, as well as 12 month updated survival results from the SYMMETRY trial of elesclomol in metastatic melanoma, were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).

8 Jun 2010

APP's lyophilized Oxaliplatin for Injection receives FDA marketing approval

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today it received approval from the U.S. Food and Drug Administration to market Oxaliplatin for Injection (lyophilized), 50 mg and 100 mg.

8 Jun 2010

Encouraging healthy lifestyle changes helps reduce aging relative's risk of cancer, say experts

Family members can help reduce an aging relative's risk of cancer by encouraging healthy lifestyle changes, according to experts at The University of Texas MD Anderson Cancer Center.

8 Jun 2010

Targeted therapy that benefits patients with metastatic colon cancer fails to help patients with stage III cancer

To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone.

7 Jun 2010

Bowel cancer affecting more and more Australians

Bowel cancer or colon cancer was till now considered a disease that affected elderly men. Recent trends however show that it is affecting more and more Australians in a younger age group.

6 Jun 2010

Multiple study data on Agendia's MammaPrint, BluePrint, and ColoPrint assays to be presented at 2010 ASCO

Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia's assays MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. MammaPrint, the company's lead product, is the only FDA-cleared breast cancer recurrence test.

5 Jun 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Researchers from University Hospitals Case Medical Center's Ireland Cancer Center will present new clinical research findings at the 46th Annual Meeting of The American Society of Clinical Oncology June 4-8 in Chicago.

5 Jun 2010

USC to present promising new findings in cancer research at 2010 ASCO

Faculty at the University of Southern California (USC) and USC Norris Comprehensive Cancer Center will present promising new findings in a number of cancer research areas at the 2010 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from June 4-8.

5 Jun 2010

Stage III colon cancer patients treated with 5-FU-based chemotherapy after 1995 have improved overall survival

Patients with stage III colon cancer treated with 5-FU-based chemotherapy after complete surgical removal of their tumor after 1995 had improved overall survival with no change in time to recurrence compared to patients treated before 1995. In contrast, patients with stage II colon cancer treated after 1995 had longer time to recurrence and time from recurrence to death compared to those patients treated prior to 1995, according to Mayo Clinic and Gr Hospitalier Pitie-Salpetriere, Paris, researchers.

4 Jun 2010

ASGE issues guidelines on ethnicity, gastrointestinal diseases and endoscopic procedures

The American Society for Gastrointestinal Endoscopy (ASGE) has issued guidelines addressing ethnicity, gastrointestinal diseases and endoscopic procedures. The guideline suggests that colorectal cancer screening should begin at age 45 for average risk African-American men and women, and that it is recommended that colorectal cancer screening be emphasized for other minority ethnic groups that have lower screening utilization rates.

4 Jun 2010

Local anesthetics may have potential therapeutic effects on IBD

Inflammatory bowel disease (IBD) is a disease of the gastrointestinal tract, mainly the intestines that may occur in the people who have genetic potential with a contribution of environmental factors.

3 Jun 2010

Perrigo acquires rights to Novel Laboratories' pending ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit

Perrigo Company announced on May 26, 2010 that it had acquired rights to Novel Laboratories' pending ANDA for HalfLytely® and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution and bisacodyl delayed-release tablets).

2 Jun 2010

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

EntreMed, Inc., today announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models. The results of the study, conducted by EntreMed collaborators at the University of Colorado School of Medicine, were published in the June 1, 2010 issue of Clinical Cancer Research (Vol. 16, Issue 11).

2 Jun 2010

Study demonstrates diagnostic, economic benefits of AABT for lung cancer patients

Oncimmune LLC, maker of EarlyCDT-Lung, a simple blood test that aids physicians in risk assessment and the early detection of lung cancer, today announced validation study results demonstrating the diagnostic and economic benefits of a standardized and reproducible autoantibody laboratory test that may significantly improve the prognosis for lung cancer patients.

2 Jun 2010

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea

Santarus, Inc., a specialty biopharmaceutical company, today announced that is has begun to enroll patients in the first study in its Phase III clinical program to evaluate the efficacy and safety of rifamycin SV MMX® for the treatment of patients with travelers' diarrhea.

2 Jun 2010

Oncimmune develops new blood test to aid early detection of cancer

The University of Nottingham spin-out company, Oncimmune Ltd, has developed a ground breaking blood test which will aid the detection of cancer as much as five years earlier than current testing methods such as mammography and CT scans. Physicians will know the result of their patient's test within one week of sending in a blood sample to Oncimmune.

2 Jun 2010

PET and CT colonography combination may provide suitable alternative for detecting polyps: Study

A study published in the June issue of The Journal of Nuclear Medicine shows that positron emission tomography -a molecular imaging technique-combined with computer tomography colonography may provide a suitable alternative for detecting polyps and cancer in the colon. This particular imaging method may be especially desirable for patients because it does not require sedation or bowel preparation.

2 Jun 2010

Cancer patients should find ways to be physically active during and after treatment: New national guidelines

Cancer patients who've been told to rest and avoid exercise can - and should - find ways to be physically active both during and after treatment, according to new national guidelines. Kathryn Schmitz, PhD, MPH, an associate professor of Epidemiology and Biostatistics and a member of the Abramson Cancer Center at the University of Pennsylvania School of Medicine, will present these guidelines at an educational session at the 2010 meeting of the American Society of Clinical Oncology, aimed at making cancer exercise rehabilitation programs as common as those offered to people who have had heart attacks or undergone cardiac surgery.

2 Jun 2010

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

AMRI announced today that on-going results from its Phase I clinical study on its novel tubulin inhibitor, ALB 109564(a), were published on the website of the American Society of Clinical Oncology (abstract.asco.org/alb). These results indicate that ALB 109564(a) is well tolerated at the doses tested and shows preliminary evidence of clinical activity in disease types not typically treated with approved vinca alkaloids.

2 Jun 2010

Colon News and Research

Give a Scan: First open access website for CT scans and clinical data

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

APP's lyophilized Oxaliplatin for Injection receives FDA marketing approval

Encouraging healthy lifestyle changes helps reduce aging relative's risk of cancer, say experts

Targeted therapy that benefits patients with metastatic colon cancer fails to help patients with stage III cancer

Bowel cancer affecting more and more Australians

Multiple study data on Agendia's MammaPrint, BluePrint, and ColoPrint assays to be presented at 2010 ASCO

New clinical research findings on oncology to be highlighted at ASCO 2010

USC to present promising new findings in cancer research at 2010 ASCO

Stage III colon cancer patients treated with 5-FU-based chemotherapy after 1995 have improved overall survival

ASGE issues guidelines on ethnicity, gastrointestinal diseases and endoscopic procedures

Local anesthetics may have potential therapeutic effects on IBD

Perrigo acquires rights to Novel Laboratories' pending ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

Study demonstrates diagnostic, economic benefits of AABT for lung cancer patients

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea

Oncimmune develops new blood test to aid early detection of cancer

PET and CT colonography combination may provide suitable alternative for detecting polyps: Study

Cancer patients should find ways to be physically active during and after treatment: New national guidelines

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News